

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 001-40227

FINCH THERAPEUTICS GROUP, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

75 State Street, Suite 100
Boston, Massachusetts
(Address of principal executive offices)

82-3433558

(I.R.S. Employer
Identification No.)

02109
(Zip Code)

Registrant's telephone number, including area code: (617) 229-6499

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	FNCH	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input checked="" type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of August 9, 2024 there were 1,605,763 outstanding shares of the registrant's common stock, par value \$0.001 per share.

FINCH THERAPEUTICS GROUP, INC.
FORM 10-Q
For the quarterly period ended June 30, 2024

Table of Contents

	<u>Page</u>
<u>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</u>	ii
<u>SPECIAL NOTE REGARDING COMPANY REFERENCES</u>	ii
<u>SPECIAL NOTE REGARDING TRADEMARKS</u>	ii
PART I. <u>FINANCIAL INFORMATION</u>	1
Item 1. <u>Condensed Consolidated Financial Statements (Unaudited)</u>	1
<u>Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023</u>	1
<u>Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2024 and 2023</u>	2
<u>Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2024 and 2023</u>	3
<u>Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023</u>	4
<u>Notes to Condensed Consolidated Financial Statements</u>	5
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	13
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	18
Item 4. <u>Controls and Procedures</u>	18
PART II. <u>OTHER INFORMATION</u>	20
Item 1. <u>Legal Proceedings</u>	20
Item 1A. <u>Risk Factors</u>	20
Item 5. <u>Other Information</u>	22
Item 6. <u>Exhibits</u>	22
<u>Signatures</u>	23

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would,” or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

- our expectations with respect to our microbiome technology and related portfolio of intellectual property and microbiome assets, and our objectives to realize the value of our intellectual property estate through licensing our technology to collaboration partners and enforcing our patent rights against third parties using infringing technologies;
- the initiation, timing, progress and results of our efforts to prosecute, enforce and license our patent portfolio;
- our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
- our intellectual property position, including the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering product candidates developed using our microbiome technology;
- our ability to fund our working capital requirements and to obtain additional funding for our operations; and
- our financial performance.

These forward-looking statements are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and are not guarantees of future performance or development. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023 and in any other reports we file with the Securities and Exchange Commission, including this Quarterly Report on Form 10-Q. Moreover, we operate in a competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

You should read this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in our forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to new information, actual results or changes in our expectations, except as required by law. We qualify all of our forward-looking statements by these cautionary statements.

SPECIAL NOTE REGARDING COMPANY REFERENCES

Unless the context otherwise requires, references in this Quarterly Report on Form 10-Q to “FTG,” the “Company,” “we,” “us” and “our” refer to Finch Therapeutics Group, Inc., and its subsidiaries.

SPECIAL NOTE REGARDING TRADEMARKS

All trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.

PART I—FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements.

FINCH THERAPEUTICS GROUP, INC.
Condensed Consolidated Balance Sheets
(Unaudited, in thousands, except share and per share data)

	June 30, 2024	December 31, 2023
Assets		
Current assets:		
Cash and cash equivalents	\$ 16,035	\$ 25,124
Prepaid expenses and other current assets	1,244	723
Total current assets	17,279	25,847
Property and equipment, net	507	594
Operating right-of-use assets	25,441	26,584
Restricted cash, non-current	2,349	2,348
Total assets	<u>\$ 45,576</u>	<u>\$ 55,373</u>
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable	\$ 29	\$ 141
Accrued expenses and other current liabilities	2,339	2,220
Operating lease liabilities, current	2,094	1,723
Total current liabilities	4,462	4,084
Operating lease liabilities, non-current	26,895	28,403
Total liabilities	31,357	32,487
Commitments and contingencies (Note 8)		
Preferred stock (undesignated), \$0.001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2024 and December 31, 2023	—	—
Stockholders' equity:		
Common stock, \$0.001 par value; 200,000,000 shares authorized and 1,605,763 shares issued and outstanding as of June 30, 2024 and December 31, 2023	2	2
Additional paid-in capital	373,322	373,279
Accumulated deficit	(359,105)	(350,395)
Total stockholders' equity	14,219	22,886
Total liabilities and stockholders' equity	<u>\$ 45,576</u>	<u>\$ 55,373</u>

See notes to unaudited condensed consolidated financial statements.

FINCH THERAPEUTICS GROUP, INC.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except share and per share data)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Revenue:				
Collaboration revenue	\$ —	\$ —	\$ —	\$ 107
Total revenue	—	—	—	107
Operating expenses:				
Research and development	—	203	—	7,199
General and administrative	6,109	8,877	11,273	18,494
Impairment of in-process research and development	—	—	—	32,900
Impairment of long-lived assets	—	—	—	13,141
Restructuring	—	801	34	4,037
Total operating expenses	6,109	9,881	11,307	75,771
Net loss from operations	(6,109)	(9,881)	(11,307)	(75,664)
Other income, net:				
Interest income, net	227	420	507	845
Gain on lease termination	—	752	—	752
Loss on loan extinguishment	—	—	—	(1,366)
Gain on sale and disposal of fixed assets, net	—	754	—	617
Sublease and other income	1,048	1,005	2,090	2,058
Total other income, net	1,275	2,931	2,597	2,906
Loss before income taxes	(4,834)	(6,950)	(8,710)	(72,758)
Income tax benefit	—	—	—	3,461
Net loss	\$ (4,834)	\$ (6,950)	\$ (8,710)	\$ (69,297)
Net loss per share attributable to common stockholders—basic and diluted (Note 11)	\$ (3.01)	\$ (4.33)	\$ (5.42)	\$ (43.21)
Weighted-average common stock outstanding—basic and diluted	1,605,763	1,604,795	1,605,763	1,603,811

See notes to unaudited condensed consolidated financial statements.

FINCH THERAPEUTICS GROUP, INC.
Condensed Consolidated Statements of Stockholders' Equity
(Unaudited, in thousands, except share and per share data)

	Common Stock \$0.001 Par Value		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
	Shares	Amount			
Balance, January 1, 2023	1,601,717	\$ 2	\$ 371,350	\$ (275,641)	\$ 95,711
Vesting of restricted stock units	3,044	—	—	—	—
Stock-based compensation	—	—	1,180	—	1,180
Net loss	—	—	—	(62,347)	(62,347)
Balance, March 31, 2023	1,604,761	2	372,530	(337,988)	34,544
Stock-based compensation	—	—	300	—	300
Net loss	—	—	—	(6,950)	(6,950)
Balance, June 30, 2023	1,604,761	\$ 2	\$ 372,830	\$ (344,938)	\$ 27,894

	Common Stock \$0.001 Par Value		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
	Shares	Amount			
Balance, January 1, 2024	1,605,763	\$ 2	\$ 373,279	\$ (350,395)	\$ 22,886
Stock-based compensation	—	—	28	—	28
Net loss	—	—	—	(3,876)	(3,876)
Balance, March 31, 2024	1,605,763	2	373,307	(354,271)	19,038
Stock-based compensation	—	—	15	—	15
Net loss	—	—	—	(4,834)	(4,834)
Balance, June 30, 2024	1,605,763	\$ 2	\$ 373,322	\$ (359,105)	\$ 14,219

See notes to unaudited condensed consolidated financial statements.

FINCH THERAPEUTICS GROUP, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)

	Six Months Ended June 30,	
	2024	2023
Cash used in operating activities:		
Net loss	\$ (8,710)	\$ (69,297)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation expense	87	1,424
Stock-based compensation expense	43	1,480
Impairment of in-process research and development	—	32,900
Impairment of long-lived assets	—	13,141
Gain on lease termination	—	(752)
Loss on loan extinguishment	—	1,366
Gain on sale and disposal of property and equipment	—	(617)
Non-cash operating lease and interest cost	1,143	1,939
Benefit for deferred income taxes	—	(3,461)
Changes in operating assets and liabilities:		
Accounts receivable	—	144
Prepaid expenses and other current assets	(521)	921
Other non-current assets	—	4,033
Accounts payable	(112)	(664)
Accrued expenses and other current liabilities	119	(2,676)
Other non-current liabilities	—	(50)
Operating lease liabilities	(1,137)	(2,369)
Net cash used in operating activities	<u>(9,088)</u>	<u>(22,538)</u>
Cash provided by investing activities:		
Proceeds on sale of property and equipment	—	1,270
Purchases of property and equipment	—	(14)
Net cash provided by investing activities	<u>—</u>	<u>1,256</u>
Cash used in financing activities:		
Repayment of loan	—	(15,000)
Payment of loan prepayment and termination fee and other	—	(1,155)
Net cash used in financing activities	<u>—</u>	<u>(16,155)</u>
Net change in cash, cash equivalents and restricted cash	(9,088)	(37,437)
Cash, cash equivalents and restricted cash at beginning of period	27,472	73,805
Cash, cash equivalents and restricted cash at end of period	<u>\$ 18,384</u>	<u>\$ 36,369</u>

See notes to unaudited condensed consolidated financial statements.

FINCH THERAPEUTICS GROUP, INC.
Notes to Condensed Consolidated Financial Statements
(Unaudited)

1. Nature of Operations and Basis of Presentation

Business

Finch Therapeutics Group, Inc. (the “Company” or “FTG”) was incorporated in 2017 as a Delaware corporation. The Company was formed as a result of a merger and recapitalization of Finch Therapeutics, Inc. (“Finch”) and Crestovo Holdings LLC (“Crestovo”) in September 2017 (the “Merger”), in which the former owners of Finch and Crestovo were issued equivalent stakes in the newly formed company, FTG. Crestovo was renamed Finch Therapeutics Holdings LLC in November 2020 (“Finch Holdings”). Finch and Finch Holdings are both wholly owned subsidiaries of FTG.

The Company is a microbiome technology company with a portfolio of intellectual property and microbiome assets. In January 2023, the Company announced the decision to wind down its development efforts and focus on realizing the value of its intellectual property estate and other assets.

Liquidity and Capital Resources

The Company currently forecasts that its unrestricted cash and cash equivalents of \$16.0 million as of June 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months beyond the date of issuance of the condensed consolidated financial statements. However, due to the consideration of certain qualitative factors, including the Company’s recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, and uncertainty around its ability to successfully realize the full value of its intellectual property estate and other assets, the Company has concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company does not currently expect to progress any product candidate through clinical trials or commercial approval and it does not currently expect to generate any revenue from product sales. The Company may never succeed in realizing the value of its intellectual property estate and other assets and, even if it does, it may never generate revenue that is significant or large enough to achieve profitability.

As a result, the Company may need additional funding to support its operating activities as it seeks to realize value from its intellectual property estate and other assets. Until such time, if ever, that the Company can generate substantial revenue, the Company may seek to finance its cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. If the Company is unable to obtain funding as needed, it may decide to pursue a dissolution and liquidation.

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of Article 10 of Regulation S-X of the Securities Act of 1933, as amended, published by the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes the disclosures are adequate. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 25, 2024.

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments that are necessary for a fair presentation of the Company’s condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023, condensed consolidated statements of operations for the three and six months ended June 30, 2024 and 2023, condensed consolidated statements of stockholders’ equity for the three and six months ended June 30, 2024 and 2023, and condensed consolidated statements of cash flows for the six months ended June 30, 2024 and 2023. Such adjustments are of a normal and recurring nature. The results of operations for the six months ended June 30, 2024 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2024. The condensed consolidated balance sheet as of

December 31, 2023 has been derived from the audited consolidated financial statements of the Company but does not include all disclosures required by U.S. GAAP.

2. Summary of Significant Accounting Policies

Significant Accounting Policies

The significant accounting policies and estimates used in preparation of the unaudited interim condensed consolidated financial statements are described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 25, 2024. There have been no material changes to the Company's significant accounting policies during the six months ended June 30, 2024.

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards has had or may have a material impact on the condensed consolidated statements or disclosures.

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, Improvements to Reportable Segment Disclosures. This standard update requires additional interim and annual disclosures about a reportable segment's expenses, even for companies with only one reportable segment. The guidance applies to all public entities and is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of these amendments on its disclosures, but this standard update will not impact the Company's results of operations or financial position.

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This standard update requires additional interim and annual disclosures about a company's income taxes, including more detailed information around the annual rate reconciliation and income taxes paid. The standard applies to all entities subject to income taxes. For public business entities, the new requirements will be effective for annual periods beginning after December 15, 2024. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of these amendments on its disclosures, but this standard update will not impact the Company's results of operations or financial position.

3. Balance Sheet Information

Cash, cash equivalents and restricted cash

Cash, cash equivalents and restricted cash consisted of the following (in thousands):

	June 30, 2024	December 31, 2023
Cash and cash equivalents	\$ 16,035	\$ 25,124
Restricted cash	2,349	2,348
Total cash, cash equivalents and restricted cash	<u>\$ 18,384</u>	<u>\$ 27,472</u>

Non-current restricted cash primarily consists of a security deposit on the Company's operating lease.

Prepaid expenses and other current assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	June 30, 2024	December 31, 2023
Prepaid insurance	\$ 917	\$ 427
Other prepaid expenses and other current assets	327	296
Total accrued expenses and other current liabilities	<u>\$ 1,244</u>	<u>\$ 723</u>

Property and equipment

Property and equipment consisted of office furniture and fixtures totaling \$0.9 million as each of June 30, 2024 and December 31, 2023. There was corresponding accumulated depreciation of \$0.4 million and \$0.3 million as of June 30, 2024 and December 31, 2023, respectively. Depreciation expense was \$0.1 million and \$1.4 million for the six months ended June 30, 2024 and 2023, respectively. During the quarter ended March 31, 2023, the Company recorded an impairment charge of \$13.1 million to its long-lived

assets, as it was determined that certain equipment, leasehold improvements, and software associated with program development would no longer be used.

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	June 30, 2024	December 31, 2023
Legal and professional fees	\$ 2,228	\$ 1,301
Refundable tax credit	—	418
Restructuring costs	—	260
Accrued compensation and benefits	18	125
Accrued other	93	116
Total accrued expenses and other current liabilities	<u>\$ 2,339</u>	<u>\$ 2,220</u>

4. Fair Value Measurement

The Company has no assets or liabilities classified as Level 2 or 3 on its condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023. The following table presents information about the Company's financial assets and liabilities measured at fair value on a recurring basis classified as Level 1 of the fair value hierarchy as follows (in thousands):

	Balance Sheet Classification	June 30, 2024	December 31, 2023
Money market funds	Cash and cash equivalents	<u>\$ 15,835</u>	<u>\$ 24,919</u>

There were no transfers between fair value levels during the six months ended June 30, 2024 and the year ended December 31, 2023. The carrying values of prepaid expenses, other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.

5. Leases

Hood Lease

On August 3, 2021, the Company entered into a 10-year lease agreement with Hood Park LLC (the "Hood Lease"), pursuant to which the Company leased approximately 61,139 square feet of office and laboratory space (the "Premises"). The Company recorded lease expense related to the Hood Lease of \$2.4 million and \$2.7 million for the six months ended June 30, 2024 and 2023, respectively.

The Company subleases the Premises. For the six months ended June 30, 2024 and 2023, the Company recognized sublease income of \$2.1 million and \$1.9 million, respectively, which is presented as other income in the condensed consolidated statements of operations.

Other Nominal Leases

The Company was party to two other nominal leases, one of which ended in February 2023 and the other of which ended in June 2023. The Company's lease expense under these leases was \$0.7 million for the six months ended June 30, 2023.

The following table presents the classification of the right-of-use asset and operating lease liabilities (in thousands):

	Balance Sheet Classification	June 30, 2024	December 31, 2023
Assets:			
Operating lease assets	Operating right-of-use assets	<u>\$ 25,441</u>	<u>\$ 26,584</u>
Liabilities			
Operating lease liabilities			
Current	Operating lease liabilities, current	\$ 2,094	\$ 1,723
Noncurrent	Operating lease liabilities, non-current	26,895	28,403
Total lease liabilities		<u>\$ 28,989</u>	<u>\$ 30,126</u>

The following table represents the components of operating lease cost, which are included in general and administrative and research and development expense, and sublease income, which is included in other income on the statement of operations for the three and six months ended June 30, 2024 and 2023 (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Operating lease cost	\$ 1,202	\$ 1,678	\$ 2,404	\$ 3,405
Short-term lease cost	—	4	—	17
Variable lease cost	578	87	999	532
Sublease income	(1,048)	(959)	(2,090)	(1,919)
Total lease cost, net	\$ 732	\$ 810	\$ 1,313	\$ 2,035

The weighted-average remaining operating lease term and discount rate as of June 30, 2024 and December 31, 2023 were as follows (in thousands):

	June 30, 2024	December 31, 2023
Weighted-average remaining lease term (years)	7.5	8.0
Weighted-average discount rate	8.5%	8.5%

Supplemental disclosure of cash flow information related to operating leases for the six months ended June 30, 2024 and 2023 was as follows (in thousands):

	2024	2023
Changes in operating lease liabilities	\$ (1,137)	\$ (2,369)

The following table represents a summary of the Company's future operating lease payments required as of June 30, 2024 (in thousands):

2024	\$ 1,998
2025	4,931
2026	5,071
2027	5,215
2028	5,364
Thereafter	17,026
Total future minimum lease payments	39,605
Less: amount representing interest	(10,616)
Present value of future minimum lease payments	\$ 28,989

The undiscounted cash flows to be received under the operating subleases as of June 30, 2024 were as follows (in thousands):

2024	\$ 2,127
2025	3,135
	\$ 5,262

6. Restructuring

The Company recognized nominal restructuring charges during the three and six months ended June 30, 2024. During the three and six months ended June 30, 2023, the Company recognized restructuring charges of \$0.8 million and \$4.0 million, respectively, primarily consisting of one-time severance payments, healthcare coverage, outplacement services and related expenses in connection with restructuring activities undertaken in January 2023. These restructuring activities were substantially completed in the fourth quarter of 2023 and all restructuring payments were completed as of June 30, 2024. The Company incurred total charges of \$3.9 million. The accrued restructuring liability as of December 31, 2023 is included in accrued expenses and other current liabilities.

The following table summarizes the restructuring accrual activity for the six months ended June 30, 2024 and 2023 (in thousands):

	2024	2023
Accrued restructuring liability, beginning of the period	\$ 260	\$ 201
Restructuring charges	34	4,037
Cash payments	(294)	(2,776)
Accrued restructuring liability, end of the period	\$ —	\$ 1,462

7. Income Taxes

During the six months ended June 30, 2024 and the year ended December 31, 2023, the Company recorded a full valuation allowance on federal and state deferred tax assets since management does not forecast the Company to be in a profitable position in the near future. There were no material changes in the Company's tax position in the six months ended June 30, 2024 as compared to the year ended December 31, 2023. The benefit for the six months ended June 30, 2023 reflects the full removal of the deferred tax liability on the in-process research and development ("IPR&D") that was written off during the first quarter of 2023 and treated as a discrete item in the tax provision.

8. Commitments and Contingencies

Legal Contingencies

On December 1, 2021, Rebiotix Inc. and Ferring Pharmaceuticals Inc. (collectively, "Rebiotix") filed a complaint against the Company in the U.S. District Court for the District of Delaware (the "Court"). The complaint seeks a declaratory judgment of non-infringement and invalidity with respect to seven United States Patents owned by the Company: U.S. Patent Nos. 10,675,309 (the "'309 Patent"); 10,463,702 (the "'702 Patent"); 10,328,107 (the "'107 Patent"); 10,064,899; 10,022,406 (the "'406 Patent"); 9,962,413 (the "'413 Patent"); and 9,308,226. On February 7, 2022, the Company filed an answer and counterclaims against Rebiotix for infringement of the '107, '702, and '309 Patents. In June 2022, Finch alleged infringement of the '406 and '413 Patents by Rebiotix. On March 7, 2022, the Company filed an amended answer and counterclaims, in which the Company, together with the Regents of the University of Minnesota ("UMN"), alleged infringement by Rebiotix of three U.S. Patents owned by UMN and exclusively licensed to the Company: U.S. Patent Nos. 10,251,914, 10,286,011, and 10,286,012, (collectively, the "UMN Patents"). On April 4, 2022, Rebiotix filed counterclaims for declaratory judgment of non-infringement and invalidity of the UMN Patents. On May 2, 2022, the Company and UMN responded, denying such counterclaims. The Court set a trial date for a five-day trial beginning on May 20, 2024. On January 23, 2023, the Company filed a second amended answer and counterclaims, in which the Company alleged infringement by Rebiotix of two additional U.S. Patents owned by Finch: U.S. Patent Nos. 11,541,080 (the "'080 Patent") and 11,491,193 (the "'193 Patent"). On February 7, 2023, Rebiotix filed counterclaims for declaratory judgment of non-infringement and invalidity of the '080 Patent and '193 Patent. The Court issued a claim construction order on February 28, 2023. On July 6, 2023, Rebiotix filed a motion to dismiss certain counts of our second amended answer and counterclaims based on the assertion that Finch lacks standing to sue as to the '107 Patent, '702 Patent, '309 Patent, '406 Patent, '413 Patent, '193 Patent, and '080 Patent. Rebiotix specifically alleges that the sole named inventor on these patents, Thomas J. Borody, did not assign his rights in those patents to Finch, and as a result, Finch does not own them and therefore does not have standing to assert them. Briefing on this motion is complete. The parties have mutually agreed to narrow the case to include only claims from the '309, '702, '193, '080, '914, and '012 Patents. On December 8, 2023, both parties filed dispositive motions asking the Court to resolve certain aspects of the case in advance of the jury trial. On February 21, 2024, the Company received a notice that the U.S. District Court for the District of Delaware issued an order resetting the trial date from May 20, 2024 to August 5, 2024. On April 15, 2024, Rebiotix filed a motion for leave to amend its Reply and Counterclaims to add a counterclaim of infringement of U.S. Patent 11,944,654 against UMN by UMN's MTP-101-LR product or, in the alternative, add an affirmative defense to patent infringement claims based on the '914 and '012 patents, but has since narrowed its motion to drop its proposed counterclaim, maintaining its motion only as to its unclean hands affirmative defense. On August 1, 2024, Ferring stipulated that the Company owns the asserted Finch patents.

On August 5, 2024, the case went to trial in the U.S. District Court for the District of Delaware. The trial involved a total of five asserted patent claims from three patents. Two claims were asserted from each of the '309 Patent and the '080 Patent owned by the Company, and one claim was asserted from the '914 Patent owned by UMN. On August 9, 2024, the jury rendered a verdict finding that Rebiotix had infringed the asserted claims, that such infringement was willful, that one claim each from the '309 Patent and the '080 Patent was invalid, and that the remaining claims were not invalid. The jury awarded royalty damages to the Company and UMN in the amount of a \$25.0 million upfront payment and \$0.815 million in running royalties for commercial sales of Rebyota, a microbiome-based therapy for the treatment of recurrent infection of *Clostridioides difficile* marketed by Ferring Pharmaceuticals Inc. ("Ferring"), for the period between its commercial launch through the date of trial. The Company and UMN expect to seek enhanced damages, attorney's fees, costs, and prejudgment interest, as well as post-judgment relief for Ferring's ongoing infringement. The Company expects Rebiotix to file post-trial motions, including seeking resolution of their pending motion to amend the pleadings and

their equitable estoppel defense as to the UMN patent. The Company also expects Rebiotix to pursue an appeal of any judgment entered on the jury's verdict.

The final outcome of the lawsuit is subject to inherent uncertainties, and the actual legal fees and costs and the amount of recovery, if any, after deducting legal fees and costs will depend upon many unknown factors, including the ultimate resolution of the proceedings. The outcome of the pending lawsuit cannot be predicted with certainty. The Company has determined that there is no probable or estimable loss contingency that is required to be recorded as of June 30, 2024.

License and Royalty Payments

The Company is party to license agreements under which it is obligated to make milestone and royalty payments and incurs annual maintenance fees.

The Company owes a nominal annual maintenance fee under its license agreement with the UMN, as well as escalating minimum royalty amounts. The minimum payments continue in perpetuity until the agreement is terminated. Upon product commercialization, the Company will be required to pay minimum royalties of \$20 thousand under a license agreement for patents owned by Arizona State University.

Under an agreement with Microbiome Health Research Institute, Inc. ("OpenBiome"), the Company is required to pay certain milestone fees of up to \$26.0 million upon the occurrence of certain research and development ("R&D") events, regulatory approvals, and commercial sales, and low single digit royalties on net sales of products on a product-by-product and country-by-country basis, as well as a mid-single digit royalties on sublicensing revenue related to such products.

9. Stockholders' Equity

The Company's amended and restated certificate of incorporation authorizes the issuance of up to 200,000,000 shares of \$0.001 par value common stock and up to 10,000,000 shares of \$0.001 par value undesignated preferred stock. As of June 30, 2024, no shares of preferred stock were outstanding. Each share of common stock entitles the holder to one vote, together with the holders of any preferred stock outstanding, on all matters submitted to the stockholders for a vote. Common stockholders are also entitled to receive dividends. As of June 30, 2024, no cash dividends have been declared or paid.

As of June 30, 2024 and December 31, 2023 the Company has reserved 44,629 and 51,331 shares of common stock, respectively, for the exercise of stock options granted pursuant to its 2021 Equity Incentive Plan (the "2021 Plan").

10. Stock-Based Compensation

2021 Equity Incentive Plan

The 2021 Plan provides for the grant of incentive stock options to employees, including employees of any parent or subsidiary of the Company, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of the Company's affiliates. During the six months ended June 30, 2024, no awards have been granted under the 2021 Plan and all previously awarded restricted stock units had vested as of December 31, 2023.

On January 1, 2024, the number of shares of common stock reserved for issuance under the 2021 Plan automatically increased in accordance with the terms of the plan by 53,288 shares. As of June 30, 2024, there were 44,629 shares of common stock issuable upon the exercise of outstanding options and there were 344,269 shares available for future issuance.

2021 Employee Stock Purchase Plan

The 2021 Employee Stock Purchase Plan (the "2021 ESPP") provides participating employees with the opportunity to purchase shares of the Company's common stock. The occurrence and duration of offering periods under the 2021 ESPP are subject to the determinations of the compensation committee of the Board of Directors. There were no offerings during the six months ended June 30, 2024. The number of shares of common stock reserved for issuance under the 2021 ESPP automatically increases on January 1 of each year in accordance with the terms of the plan. On January 1, 2024, the number of shares of common stock reserved for

issuance under the 2021 ESPP increased by 10,657 shares. As of June 30, 2024, 3,354 shares have been issued under the 2021 ESPP and 55,824 shares are available for future issuance.

Stock Options

The following table summarizes the activity of the Company's stock options for the six months ended June 30, 2024:

	Shares	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (in years)
Outstanding as of December 31, 2023	51,331	\$ 39.05	8.0
Granted	—	\$ —	
Cancelled or forfeited	(128)	\$ 149.99	
Expired	(6,574)	\$ 154.34	
Outstanding as of June 30, 2024	44,629	\$ 21.75	8.1
Options exercisable as of June 30, 2024	20,558	\$ 37.70	7.2
Options vested or expected to vest as of June 30, 2024	44,629	\$ 21.75	8.1

As of June 30, 2024, the stock options had no intrinsic value and there was approximately \$0.1 million of unrecognized compensation expense remaining to be recognized under the 2021 Plan. The Company expects to recognize this cost over a weighted average period of 2.9 years.

Stock-Based Compensation Expense

Total stock-based compensation expense for the three and six months ended June 30, 2024 and 2023 was recorded as follows (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Research and development	\$ —	\$ —	\$ —	\$ 231
General and administrative	15	300	43	1,249
Total	\$ 15	\$ 300	\$ 43	\$ 1,480

11. Loss Per Share

Basic and diluted loss per share for the three and six months ended June 30, 2024 and 2023, which is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding, is as follows (in thousands, except share and per share data):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Numerator:				
Net loss and net loss attributable to common stockholders—basic and diluted	\$ (4,834)	\$ (6,950)	\$ (8,710)	\$ (69,297)
Denominator:				
Weighted-average common stock outstanding—basic and diluted	1,605,763	1,604,795	1,605,763	1,603,811
Net loss per share attributable to common stockholders—basic and diluted	\$ (3.01)	\$ (4.33)	\$ (5.42)	\$ (43.21)

The weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with (1) our condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and (2) the audited consolidated financial statements and the related notes and management’s discussion and analysis of financial condition and results of operations for the fiscal year ended December 31, 2023 included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission, or SEC, on March 25, 2024, which we refer to as the 2023 10-K.

Overview

We are a microbiome technology company with a portfolio of intellectual property and microbiome assets. Our objectives are to realize the value of our intellectual property estate through licensing our technology to collaboration partners and enforcing our patent rights against infringing parties through intellectual property litigation and, in certain cases, to generate additional data on selected product candidates through academic collaborations. In January 2023, we began focusing on realizing the value of our intellectual property estate and other assets. We have significantly scaled back our expenses by winding down our clinical development efforts, including liquidating certain of our assets, terminating vendor contracts and reducing headcount, and we now focus on realizing the value of our intellectual property and other assets (which we refer to collectively as the Strategic Reprioritization).

We do not currently expect to be able to progress any product candidate through clinical trials or commercial approval and we do not currently expect to generate any revenue from product sales. Since our inception, we have funded our operations primarily with proceeds from the sale of common and convertible preferred stock, our previous loan agreement with Hercules Capital, Inc., or Hercules, and from collaboration revenue. Since our inception, we have incurred significant operating losses. As of June 30, 2024, we had an accumulated deficit of \$359.1 million. We expect to continue to generate operating losses and negative operating cash flows for the foreseeable future as we attempt to realize the value of our intellectual property estate and other assets.

Although we believe strongly in the value of our pioneering intellectual property portfolio and the merits of our current litigation activities relating to those assets, we may never succeed in realizing the value of our intellectual property estate and other assets and, even if we do, we may never generate revenue that is significant or large enough to achieve profitability. As a result, we may need additional funding to support our operating activities as we seek to realize value from our intellectual property estate and other assets. Until such a time, if ever, that we can generate substantial revenue, we may seek to finance our cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. If we are unable to obtain funding as needed, we may decide to pursue a dissolution and liquidation.

We continue to explore opportunities to realize the value of our intellectual property and microbiome assets through strategic partnerships and academic collaborations. These include our licensing relationship with the University of Minnesota, or UMN, pursuant to which UMN is conducting multiple investigator-sponsored clinical trials using a microbiome product candidate comprised of compositions to which we hold an exclusive license. In addition to our clinical and preclinical assets, we have developed a biorepository of samples and strains that can be used in a variety of research applications and may form the basis for future collaborations.

Components of Our Results of Operations

Revenue

We have no products approved for commercial sale. We have not and do not expect to generate any revenue from the sale of licensed products in 2024. Revenue from the year ended December 31, 2023, which was earned in the first quarter of 2023, was generated primarily through a collaboration agreement that has ended. We expect that our revenue for the next several years, if any, will be derived from enforcement and out-licensing of our intellectual property estate.

Agreements with OpenBiome

We are party to a LMIC License Agreement, or the LMIC Agreement, with Microbiome Health Research Institute, Inc., or OpenBiome, pursuant to which we granted OpenBiome a non-exclusive royalty-bearing license, with the right to grant sublicenses, under certain patents, patent applications, and know-how that are reasonably necessary or useful for the exploitation of products manufactured directly from stool from a stool donor source without the use of culturing or replication, or certain natural products. The only consideration provided to us under the LMIC Agreement is in the form of potential future royalties on net sales of these products. We are entitled to receive tiered royalties on net sales of certain products, ranging from mid-single digit to low second decile digits on a product-by-product and country-by-country basis. We were also party to an asset purchase agreement, or the OpenBiome Agreement, with OpenBiome which entitles us to royalties which serve as reimbursement for third party license fees, based on certain sales.

We did not recognize any revenue related to the LMIC Agreement or the OpenBiome Agreement for each of the six months ended June 30, 2024 and 2023.

Operating Expenses

Research and Development Expenses

Until January 2023, research and development, or R&D, activities were central to our business model. As a result of our Strategic Reprioritization, we do not currently expect to be able to progress any product candidate through clinical trials or commercial approval.

R&D expenses from the year ended December 31, 2023, which were incurred in the first quarter of 2023, primarily consisted of salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in R&D functions. We expensed R&D costs as incurred.

General and Administrative Expenses

We expect general and administrative expenses to primarily consist of legal service and litigation-related costs and expenses associated with being a public company, including costs related to consulting, accounting, audit, legal, regulatory and tax compliance services, and director and officer insurance costs.

Impairment of IPR&D

In January 2023, management concluded that the Strategic Reprioritization was an impairment indicator requiring our management to perform an interim impairment test of its in-process research and development, or IPR&D, asset. Management's assessment indicated that there were no future cash flow projections associated with the IPR&D asset and the fair value was zero. This resulted in an impairment charge during the first quarter of 2023.

Impairment of Long-Lived Assets

Impairment of long-lived assets consisted of costs attributable to the cease of use of laboratory equipment, leasehold improvements, and software associated with program development, as it was determined that certain long-lived assets would no longer be used as a result of the Strategic Reprioritization.

Restructuring Expense

Restructuring expenses consist of costs directly incurred because of restructuring initiatives, and includes one-time severance payments, healthcare coverage, outplacement services and related expenses as well as contract cancellation costs.

Total Other Income, Net

Total other income, net primarily consists of sublease income and interest income. In 2023, total other income, net also included a gain on the termination of our Inner Belt Road Lease and a gain on the sale and disposal of fixed assets, partially offset by a loss on loan extinguishment with respect to our previous loan agreement with Hercules.

Income Tax Benefit

The income tax benefit reflects the full removal of the deferred tax liability associated with the IPR&D that was written off during the first quarter of 2023 and treated as a discrete item in the tax provision.

Results of Operations

Comparison of the Three Months Ended June 30, 2024 and 2023

The following table summarizes our results of operations for the three months ended June 30, 2024 and 2023 (in thousands):

	2024	2023
Operating expenses:		
Research and development	\$ —	\$ 203
General and administrative	6,109	8,877
Restructuring	—	801
Total operating expenses	6,109	9,881
Net loss from operations	(6,109)	(9,881)
Other income, net:		
Interest income, net	227	420
Gain on lease termination	—	752
Gain on sale and disposal of fixed assets, net	—	754
Sublease and other income	1,048	1,005
Total other income, net	1,275	2,931
Net loss	<u>\$ (4,834)</u>	<u>\$ (6,950)</u>

Research and Development Expenses

There were no R&D expenses for the three months ended June 30, 2024. R&D expenses totaled \$0.2 million for the three months ended June 30, 2023. The decrease was due to the Strategic Reprioritization, including our strategic shift to focusing on realizing the value of our intellectual property and other assets. This included liquidating certain of our assets, terminating vendor contracts and reducing headcount.

General and Administrative Expenses

The following table summarizes our general and administrative expenses for the three months ended June 30, 2024 and 2023 (in thousands):

	2024	2023	Increase (Decrease)
Professional fees	\$ 4,045	\$ 5,476	\$ (1,431)
Facilities and supplies	1,319	1,796	(477)
Personnel expenses (including stock-based compensation)	135	780	(645)
Other expenses	610	825	(215)
	<u>\$ 6,109</u>	<u>\$ 8,877</u>	<u>\$ (2,768)</u>

General and administrative expenses were \$6.1 million and \$8.9 million for the three months ended June 30, 2024 and 2023, respectively. The decrease of \$2.8 million was primarily due to a \$1.4 million decrease in professional fees, driven by lower legal fees, a \$0.6 million decrease in personnel expenses due to the reduction in headcount to one full time employee, a \$0.5 million decrease in facilities and supplies, driven by the termination of our Inner Belt Road lease in 2023, and a \$0.2 million decrease in other expenses, driven by our decision to significantly scale back our operations as part of the Strategic Reprioritization.

Restructuring Expense

There were no restructuring expense for the three months ended June 30, 2024. Restructuring expenses totaled \$0.8 million for the three months ended June 30, 2023. The decrease is due to no remaining costs incurred in the three months ended June 30, 2024 related to the implementation of certain expense reduction measures undertaken in January 2023 as part of the Strategic Reprioritization.

Other Income, Net

Total other income, net was \$1.3 million and \$2.9 million for the three months ended June 30, 2024 and 2023, respectively. The decrease of \$1.6 million was primarily due to the \$0.8 million gain on the termination of our Inner Belt Road Lease in 2023 and \$0.8 million gain on the sale of fixed assets in 2023.

Comparison of the Six Months Ended June 30, 2024 and 2023

The following table summarizes our results of operations for the six months ended June 30, 2024 and 2023 (in thousands):

	2024	2023
Revenue:		
Collaboration revenue	\$ —	\$ 107
Total revenue	—	107
Operating expenses:		
Research and development	—	7,199
General and administrative	11,273	18,494
Impairment of in-process research and development	—	32,900
Impairment of long-lived assets	—	13,141
Restructuring	34	4,037
Total operating expenses	11,307	75,771
Net loss from operations	(11,307)	(75,664)
Other income, net:		
Interest income, net	507	845
Gain on lease termination	—	752
Loss on loan extinguishment	—	(1,366)
Gain on sale and disposal of fixed assets, net	—	617
Sublease and other income	2,090	2,058
Total other income, net	2,597	2,906
Loss before income taxes	(8,710)	(72,758)
Income tax benefit	—	3,461
Net loss	\$ (8,710)	\$ (69,297)

Revenue

There was no revenue for the six months ended June 30, 2024. Revenue of \$0.1 million for the six months ended June 30, 2023 primarily consisted of collaboration revenue.

Research and Development Expenses

There were no R&D expenses for the six months ended June 30, 2024. R&D expenses totaled \$7.2 million for the six months ended June 30, 2023. The decrease was due to the Strategic Reprioritization, including our strategic shift to focusing on realizing the value of our intellectual property and other assets. This included liquidating certain of our assets, terminating vendor contracts and reducing headcount.

General and Administrative Expenses

The following table summarizes our general and administrative expenses for the six months ended June 30, 2024 and 2023 (in thousands):

	2024	2023	Increase (Decrease)
Professional fees	\$ 7,107	\$ 9,874	\$ (2,767)
Facilities and supplies	2,712	3,636	(924)
Personnel expenses (including stock-based compensation)	287	2,868	(2,581)
Other expenses	1,167	2,116	(949)
	\$ 11,273	\$ 18,494	\$ (7,221)

General and administrative expenses were \$11.3 million and \$18.5 million for the six months ended June 30, 2024 and 2023, respectively. The decrease of \$7.2 million was primarily due to a \$2.8 million decrease in professional fees, primarily due to lower legal fees, a \$2.6 million decrease in personnel expenses due to the reduction in headcount to one full time employee, a \$0.9 million decrease in facilities and supplies, primarily due to the termination of our Inner Belt Road lease in 2023, and a \$0.9 million decrease in other expenses, primarily driven by our decision to significantly scale back our operations as part of the Strategic Reprioritization.

Restructuring Expense

Restructuring expense for the six months ended June 30, 2024 was nominal, compared to \$4.0 million for the six months ended June 30, 2023. The decrease is due to nominal costs remaining in the first quarter of 2024 related to the implementation of certain expense reduction measures undertaken in January 2023 as part of the Strategic Reprioritization.

Other Income, Net

Total other income, net was \$2.6 million and \$2.9 million for the six months ended June 30, 2024 and 2023, respectively. The decrease of \$0.3 million was primarily due to the \$0.8 million gain on the termination of our Inner Belt Road Lease in 2023 and \$0.6 million gain on the sale of fixed assets in 2023. In addition, there was a \$0.3 million decrease in interest income due to the decrease in money market funds resulting from cash used in operations. These decreases were partially offset by a loss on loan extinguishment of \$1.4 million during 2023 primarily resulting from paying off our loan balance with Hercules in January 2023.

Liquidity and Capital Resources

Sources of Liquidity

Since our inception, we have not recognized any product revenue and have incurred operating losses and negative cash flows from our operations. We do not currently expect to progress any product candidate through clinical trials or commercial approval and we do not currently expect to generate any revenue from product sales. We expect that our revenue for the next several years, if any, will be derived from enforcement and out-licensing of our intellectual property estate. We have funded our operations primarily through equity financing, debt financing, and collaboration revenue. We raised an aggregate of \$118.8 million in net proceeds from our initial public offering, approximately \$177.0 million from the sale of convertible preferred stock and \$14.0 million in collaboration revenue received under a collaboration agreement, which was terminated in 2022. In May 2022, we borrowed \$15.0 million under a loan agreement with Hercules and in January 2023, we voluntarily paid off all outstanding amounts under the loan agreement with Hercules.

Cash Flows

The following table summarizes our cash flows for the six months ended June 30, 2024 and 2023 (in thousands):

	<u>2024</u>	<u>2023</u>
Net cash used in operating activities	\$ (9,088)	\$ (22,538)
Net cash provided by investing activities	—	1,256
Net cash used in financing activities	—	(16,155)
Net decrease in cash and cash equivalents, and restricted cash	<u>\$ (9,088)</u>	<u>\$ (37,437)</u>

Operating Activities

During the six months ended June 30, 2024, cash used in operating activities was \$9.1 million compared to \$22.5 million in 2023. The decrease in cash used in operating activities is primarily due to the implementation of the Strategic Reprioritization. During the six months ended June 30, 2024, cash used in operating activities was primarily related to legal and other professional costs, employee compensation and consulting.

Investing Activities

During the six months ended June 30, 2024, there was no cash provided by investing activities. During the six months ended June 30, 2023, net cash provided by investing activities of \$1.3 million was primarily due to selling certain property and equipment as a result of the Strategic Reprioritization.

Financing Activities

During the six months ended June 30, 2024, there was no cash used in financing activities. During the six months ended June 30, 2023, cash used in financing activities of \$16.2 million was due to repaying an outstanding balance of \$15.0 million borrowed under our loan agreement with Hercules, as well as the payment of related prepayment fees.

Funding Requirements

As of June 30, 2024, our unrestricted cash and cash equivalents were \$16.0 million. We believe that our existing cash on hand will enable us to fund our operating expenses and capital expenditure requirements into 2025; however, our anticipated cash expenditures and funding requirements are largely dependent upon the outcome of our ongoing litigation against Rebiotix, which is scheduled to go to trial in August 2024. We have based this estimate on assumptions that may prove to be wrong, and we could expend our capital resources sooner than we expect. We expect to continue to incur significant losses for the foreseeable future as we attempt to realize the value of our intellectual property estate and other assets.

Material Cash Requirements

During the six months ended June 30, 2024, there were no material changes to our material cash requirements from those described under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” discussed in the 2023 10-K.

Critical Accounting Policies and Significant Judgments and Estimates

Our unaudited interim condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our unaudited interim condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our condensed financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis, and our actual results may differ from these estimates under different assumptions or conditions.

There have been no significant changes to our critical accounting policies from those described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in the 2023 10-K.

Recently Issued Accounting Pronouncements

See Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for a description of recent accounting pronouncements applicable to our financial statements.

Emerging Growth Company Status and Smaller Reporting Company Status

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. We expect to use the extended transition period for any other new or revised accounting standards during the period in which we remain an emerging growth company and, as a result, we will not adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

We will remain an emerging growth company until December 31, 2026 or, if earlier, (i) the last day of our first fiscal year in which we have total annual gross revenues of at least \$1.235 billion, (ii) the date on which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds \$700.0 million as of the prior June 30th or (iii) the date on which we have issued more than \$1.0 billion in non-convertible debt securities during the prior three-year period.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may have an impact on our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of interest rates.

Interest Rate Risk

There have been no material changes in our primary risk exposures or management of market risk from those described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in the 2023 10-K.

Item 4. Controls and Procedures

Management’s Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosures. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.

Pursuant to Rules 13(a)-13(e) and 15(d)-15(e) under the Exchange Act, management, with the participation of our principal executive officer and our principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2024. Based on the evaluation of our disclosure controls and procedures as of June 30, 2024, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the six months ended June 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at a reasonable assurance level. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

On December 1, 2021, Rebiotix Inc. and Ferring Pharmaceuticals Inc., or, collectively, Rebiotix, filed a complaint against us in the U.S. District Court for the District of Delaware, or the Court. The complaint seeks a declaratory judgment of non-infringement and invalidity with respect to seven United States Patents owned by us: U.S. Patent Nos. 10,675,309, or the '309 Patent; 10,463,702, or the '702 Patent; 10,328,107, or the '107 Patent; 10,064,899; 10,022,406, or the '406 Patent; 9,962,413, or the '413 Patent; and 9,308,226. On February 7, 2022, we filed an answer and counterclaims against Rebiotix for infringement of the '107 Patent, the '702 Patent, and the '309 Patent. In June 2022, we alleged infringement of the '406 Patent and '413 Patent by Rebiotix. On March 7, 2022, we filed an amended answer and counterclaims, in which we, together with the Regents of the University of Minnesota, or UMN, alleged infringement by Rebiotix of three U.S. Patents owned by UMN and exclusively licensed to us: U.S. Patent Nos. 10,251,914, 10,286,011, and 10,286,012, or, collectively, the UMN Patents. On April 4, 2022, Rebiotix filed counterclaims for declaratory judgment of non-infringement and invalidity of the UMN Patents. On May 2, 2022, we and UMN responded, denying such counterclaims. The Court set a trial date for a five-day trial beginning on May 20, 2024. On January 23, 2023, we filed a second amended answer and counterclaims, in which we alleged infringement by Rebiotix of two additional U.S. Patents owned by us: U.S. Patent Nos. 11,541,080, or the '080 Patent, and 11,491,193, or the '193 Patent. On February 7, 2023 Rebiotix filed counterclaims for declaratory judgment of non-infringement and invalidity of the '080 Patent and '193 Patent. The Court issued a claim construction order on February 28, 2023. On July 6, 2023, Rebiotix filed a motion to dismiss certain counts of our second amended answer and counterclaims based on the assertion that we lack standing to sue as to the '107 Patent, '702 Patent, '309 Patent, '406 Patent, '413 Patent, '193 Patent, and '080 Patent. Rebiotix specifically alleges that the sole named inventor on these patents, Thomas J. Borody, did not assign his rights in those patents to Finch, and as a result, we do not own them and therefore do not have standing to assert them. Briefing on this motion is complete. The parties have mutually agreed to narrow the case to include only claims from the '309, '702, '193, '080, '914, and '012 Patents. On December 8, 2023, both parties filed dispositive motions asking the Court to resolve certain aspects of the case in advance of the jury trial. On February 21, 2024, we received a notice that the U.S. District Court for the District of Delaware issued an order resetting the trial date from May 20, 2024 to August 5, 2024. On April 15, 2024, Rebiotix filed a motion for leave to amend its Reply and Counterclaims to add a counterclaim of infringement of U.S. Patent 11,944,654 against UMN by UMN's MTP-101-LR product or, in the alternative, add an affirmative defense to patent infringement claims based on the '914 and '012 patents, but has since narrowed its motion to drop its proposed counterclaim, maintaining its motion only as to its unclean hands affirmative defense. On August 1, 2024, Ferring stipulated that we own the asserted Finch patents.

On August 5, 2024, the case went to trial in the U.S. District Court for the District of Delaware. The trial involved a total of five asserted patent claims from three patents. Two claims were asserted from each of the '309 Patent and the '080 Patent owned by us, and one claim was asserted from the '914 Patent owned by UMN. On August 9, 2024, the jury rendered a verdict finding that Rebiotix had infringed the asserted claims, that such infringement was willful, that one claim each from the '309 Patent and the '080 Patent was invalid, and that the remaining claims were not invalid. The jury awarded royalty damages to us and UMN in the amount of a \$25.0 million upfront payment and \$0.815 million in running royalties for commercial sales of Rebyota, a microbiome-based therapy for the treatment of recurrent infection of *Clostridioides difficile* marketed by Ferring Pharmaceuticals Inc., or Ferring, for the period between its commercial launch through the date of trial. We and UMN expect to seek enhanced damages, attorney's fees, costs, and prejudgment interest, as well as post-judgment relief for Ferring's ongoing infringement. We expect Rebiotix to file post-trial motions, including seeking resolution of their pending motion to amend the pleadings and their equitable estoppel defense as to the UMN patent. We also expect Rebiotix to pursue an appeal of any judgment entered on the jury's verdict.

The final outcome of the lawsuit is subject to inherent uncertainties, and the actual legal fees and costs and the amount of recovery, if any, after deducting legal fees and costs will depend upon many unknown factors, including the ultimate resolution of the proceedings. The outcome of the pending lawsuit cannot be predicted with certainty.

We may also be a party to litigation and subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, which could materially affect our business, financial condition or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

Other than as described below, there have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 25, 2024.

Our common stock was suspended from trading on the Nasdaq, which may adversely affect our stock price and the liquidity of our common stock and could impact our ability to obtain financing.

On February 16, 2024, we received a determination letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that it believes that, as a result of our decision in January 2023 to re-orient our business strategy, including by discontinuing our Phase 3 clinical trial of CP101 in recurrent C. difficile infection and focusing on realizing the value of our intellectual property estate and other assets, we are a “public shell” under the Nasdaq criteria. As such, the Listing Qualifications Department determined that the continued listing of our common stock on the Nasdaq Global Select Market (“Nasdaq GSM”) was no longer warranted. We subsequently appealed the Nasdaq Listing Qualifications Department’s determination to delist our common stock. On May 23, 2024 we received notice from Nasdaq formally notifying us that our appeal had been rejected and Nasdaq had determined to delist the Company’s common stock from the Nasdaq GSM (the “Listing Panel Decision”). As a result, effective as of the opening of business on May 28, 2024, we were suspended from the Nasdaq GSM and began trading on the over-the-counter markets operated by OTC Markets Group Inc. Our common stock is currently trading under the symbol “FNCH” on OTC Pink.

On June 7, 2024, we requested that the Nasdaq Listing and Hearing Review Council (the “Listing Council”) review the Listing Panel Decision and on June 24, 2024 we submitted a memorandum in support of our appeal. If our appeal to the Listing Council is unsuccessful, a Form 25, notification of removal from listing, will be filed with the Securities and Exchange Commission and, upon effectiveness, our common stock will be delisted from Nasdaq.

The delisting of our common stock from the Nasdaq GSM could adversely affect our ability to attract new investors, decrease the liquidity of our outstanding shares of common stock, reduce our flexibility to raise additional capital, reduce the price at which our common stock trades and increase the transaction costs inherent in trading such shares with overall negative effects for our stockholders. In addition, broker-dealers may not continue to make a market in our common stock, and trading on the OTC Pink Market may deter certain institutions and persons from investing in our securities at all. For these reasons and others, delisting could adversely affect the price of our common stock and our business, financial condition and results of operations.

In addition, as a public company and notwithstanding the delisting of our common stock from the Nasdaq GSM, we continue to incur significant legal, accounting and other expenses and we are required to perform additional tasks, such as adopting additional internal controls, disclosure controls and procedures, and bearing all of the internal and external costs of preparing and distributing periodic public reports in compliance with our obligations under the securities laws.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit Number	Description	Incorporated by Reference			
		Schedule Form	File Number	Exhibit	Filing Date
3.1	Amended and Restated Certificate of Incorporation of Finch Therapeutics Group, Inc.	8-K	001-40227	3.1	March 23, 2021
3.2	Certificate of Amendment to the Amended and Restated Certificate of Incorporation.	8-K	001-40227	3.1	June 9, 2023
3.3	Amended and Restated Bylaws of Finch Therapeutics Group, Inc.	8-K	001-40227	3.2	March 23, 2021
31.1*	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				
31.2*	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				
32.1+	Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				
101.INS*	Inline XBRL Instance Document				
101.SCH*	Inline XBRL Taxonomy Extension Schema Document				
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document				
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document				
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document				
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document				
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)				

* Filed herewith.

+ This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

FINCH THERAPEUTICS GROUP, INC.

Date: August 13, 2024

By: /s/ Matthew P. Blischak
Matthew P. Blischak
Chief Executive Officer, President and Secretary
(Principal Executive Officer)

Date: August 13, 2024

By: /s/ Lance Thibault
Lance Thibault
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)

**CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Matthew P. Blischak, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Finch Therapeutics Group, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 13, 2024

By: /s/ Matthew P. Blischak
Matthew P. Blischak
President and Chief Executive Officer
(Principal Executive Officer)

**CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Lance Thibault, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Finch Therapeutics Group, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 13, 2024

By: /s/ Lance Thibault
Lance Thibault
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Finch Therapeutics Group, Inc. (the “Company”) for the quarter ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the company, hereby certifies, pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Exchange Act; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report.

Date: August 13, 2024

By: /s/ Matthew P. Blischak

Matthew P. Blischak
President and Chief Executive Officer
(Principal Executive Officer)

Date: August 13, 2024

By: /s/ Lance Thibault

Lance Thibault
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
